Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia

Author:

Döbert Moritz1ORCID,Varouxaki Anna Nektaria1,Mu An Chi1,Syngelaki Argyro1,Ciobanu Anca1,Akolekar Ranjit2ORCID,De Paco Matallana Catalina3,Cicero Simona4,Greco Elena5,Singh Mandeep6,Janga Deepa7,del Mar Gil Maria89ORCID,Jani Jacques C.10,Bartha José Luis11,Maclagan Kate12,Wright David13,Nicolaides Kypros H.1ORCID

Affiliation:

1. Fetal Medicine Research Institute, King’s College Hospital, London, UK (M.D., A.N.V., A.C.M., A.S., A.C., K.H.N.).

2. Medway Maritime Hospital, Gillingham, UK (R.A.).

3. Hospital Clínico Universitario Virgen de la Arrixaca and Institute for Biomedical Research of Murcia, IMIB-Arrixaca, Spain (C.D.P.M.).

4. Homerton University Hospital, London, UK (S.C.).

5. Royal London Hospital, UK (E.G.).

6. Southend University Hospital, Westcliff-on-Sea, UK (M.S.).

7. North Middlesex University Hospital, London, UK (D.J.).

8. School of Health Sciences, Universidad Francisco de Vitoria, Madrid, Spain (M.d.M.G.).

9. Hospital Universitario de Torrejón, Madrid, Spain (M.d.M.G.).

10. University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium (J.C.J.).

11. Hospital Universitario La Paz, Madrid, Spain (J.L.B.).

12. Fetal Medicine Foundation, London, UK (K.M.).

13. University of Exeter, UK (D.W.).

Abstract

Background: Effective screening for term preeclampsia is provided by a combination of maternal factors with measurements of mean arterial pressure, serum placental growth factor, and serum soluble fms-like tyrosine kinase-1 at 35 to 37 weeks of gestation, with a detection rate of ≈75% at a screen-positive rate of 10%. However, there is no known intervention to reduce the incidence of the disease. Methods: In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1120 women with singleton pregnancies at high risk of term preeclampsia to receive pravastatin at a dose of 20 mg/d or placebo from 35 to 37 weeks of gestation until delivery or 41 weeks. The primary outcome was delivery with preeclampsia at any time after randomization. The analysis was performed according to intention to treat. Results: A total of 29 women withdrew consent during the trial. Preeclampsia occurred in 14.6% (80 of 548) of participants in the pravastatin group and in 13.6% (74 of 543) in the placebo group. Allowing for the effect of risk at the time of screening and participating center, the mixed-effects Cox regression showed no evidence of an effect of pravastatin (hazard ratio for statin/placebo, 1.08 [95% CI, 0.78–1.49]; P =0.65). There was no evidence of interaction between the effect of pravastatin, estimated risk of preeclampsia, pregnancy history, adherence, and aspirin treatment. There was no significant between-group difference in the incidence of any secondary outcomes, including gestational hypertension, stillbirth, abruption, delivery of small for gestational age neonates, neonatal death, or neonatal morbidity. There was no significant between-group difference in the treatment effects on serum placental growth factor and soluble fms-like tyrosine kinase-1 concentrations 1 and 3 weeks after randomization. Adherence was good, with reported intake of ≥80% of the required number of tablets in 89% of participants. There were no significant between-group differences in neonatal adverse outcomes or other adverse events. Conclusions: Pravastatin in women at high risk of term preeclampsia did not reduce the incidence of delivery with preeclampsia. Registration: URL: https://www.isrctn.com ; Unique identifier ISRCTN16123934.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference37 articles.

1. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation

2. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease

3. Maternal Morbidity Associated With Early-Onset and Late-Onset Preeclampsia

4. Cardiovascular Disease Risk Factors After Early-Onset Preeclampsia, Late-Onset Preeclampsia, and Pregnancy-Induced Hypertension

5. Knight, M, Nair, M, Tuffnell, D, Kenyon, S, Shakespeare, J, Brocklehurst, P, Kurinczuk, JJ; MBRRACE-UK. Saving Lives, Improving Mothers’ Care: Surveillance of Maternal Deaths in the UK 2012-14 and Lessons Learned to Inform Maternity Care From the UK and Ireland Confidential Enquiries Into Maternal Deaths and Morbidity 2009-14. National Perinatal Epidemiology Unit, University of Oxford; 2016.

Cited by 72 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3